VIA
RGNX icon

Vident Investment Advisory’s Regenxbio RGNX Stock Holding History

Vident Investment Advisory’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-75,321
Closed -$1.99M – 1313
2022
Q3 		$1.99M Buy
+75,321
New +$2.23M 0.06% 367
2021
Q3 		– Sell
-5,482
Closed -$213K – 1222
2021
Q2 		$213K Buy
+5,482
New +$196K 0.01% 1030

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vident Investment Advisory's RGNX Position: Q4 2022 in Review

Vident Investment Advisory sold out of Regenxbio (RGNX) in Q4 2022, closing a stake of 75,321 shares — an estimated $1.99M sold.

Vident Investment Advisory first reported a position in RGNX in Q2 2021 and held it in 2 quarters. The position peaked at $1.99M in Q3 2022. 180 funds tracked by Wall St. Rank hold RGNX as of Q4 2022.

  • Vident Investment Advisory reported no remaining Regenxbio position as of Q4 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 75,321 Regenxbio shares in Q4 2022, an estimated $1.99M.
  • Vident Investment Advisory first reported a position in Regenxbio in Q2 2021 and held it in 2 quarters.
  • Vident Investment Advisory's Regenxbio position peaked at $1.99M in Q3 2022.
  • 180 funds tracked by Wall St. Rank held Regenxbio as of Q4 2022.

Based on Vident Investment Advisory's 13F filing for Q4 2022, filed 14 Feb 2023.